AKT1 and neoplasm: A large body of preclinical evidence suggests that AKT/mTOR pathway inhibitors can be effectively used in combination with chemotherapy, radiotherapy, and targeted agents to improve efficacy and overcome resistance, suggesting that the mTOR pathway may be a target for promoting tumor sensitivity to radiotherapy.27